Navigation Links
Antifolate in Medical News

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

...treatment regimens, including an autologous stem cell transplant for some patients. Designed to be selectively transported into tumor cells, the novel antifolate pralatrexate accumulates to high concentrations in the tumor cell, inhibiting DNA synthesis. A total of 115 patients were enrolled into this phase ...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

...treatment regimens, including an autologous stem cell transplant for some patients. Designed to be selectively transported into tumor cells, the novel antifolate pralatrexate accumulates to high concentrations in the tumor cell, inhibiting DNA synthesis. A total of 115 patients were enrolled into this ...

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Antifolate Drugs may Be Effective in Treating P Vivax Malaria

...Malaria and Leishmaniasis Control Programme in Pakistan, have revealed that antifolate drugs may be effective in treating P vivax malaria. Toby Leslie, M.Sc., and colleagues tested the relative efficacy and safety of two antifolate drugs (sulfadoxine-pyrimethamine and chlorproguanil-dapsone) against P viva...
Antifolate in Medical Technology

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

... to focus solely on oncology assets. He led the licensing effort to acquire both oncology products currently in their portfolio: pralatrexate, a novel antifolate currently in a registration trial in peripheral T-cell lymphoma, and RH1, currently in a Phase 1 trial for solid tumors. Before Allos, Mr. Malek held ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... with chemotherapy. J Clin Oncol 2004; 22:1589-97. (3) Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66:431-...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...

Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma

...ollment in a Phase 1, open-label, multi-center study of the Company's novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patie...ancer. The company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with rela...

Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting

...(tm) (talotrexin) for Injection Talvesta(tm) is a novel nonpolyglutamable antifolate drug under development for the treatment of various types of cancers. Talve...more potency in overcoming polyglutamation, a well-established mechanism of antifolate resistance. Talvesta also binds more tightly to its anti-tumor target DHFR,...
Antifolate in Biological Technology

Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

...n vitro. PDX in NSCLC (Phase 1) The poster entitled "Phase 1 study of the antifolate pralatrexate when given with vitamin B12 and folic acid supplementation in ...ancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients ...

Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...

Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...
Other Tags
(Date:4/18/2015)... "I recognized the need for a better way ... inventor from Cincinnati, Ohio. "This need inspired me to ... Slyde Door to offer an alternative to the conventional ... convenient storage space for an evacuation stretcher. The door ... , This offers added peace of mind to ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Insuranceautoquote.info has ... online auto insurance quotes . , Clients ... a single website. The online environment provides important advantages ... vehicles. , Drivers who do not have coverage ... rates during any season, day or hour. Many agencies ...
(Date:4/18/2015)... NC (PRWEB) April 18, 2015 Patients ... risk of developing mesothelioma later in life, but the ... from mesothelioma that is unrelated to radiation. Surviving Mesothelioma ... on its website. Click here to read it ... Australia compared the cases of 45 patients who had ...
(Date:4/18/2015)... 18, 2015 More than 2000 styles ... at TheCelebrityDresses.com, the #1 online store carrying celebrity inspired ... girls have got their perfect dresses for their prom. ... fashion prom dresses at TheCelebrityDresses.com would be an ideal ... than 2000 prom dresses inspired by the most loved ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as ... the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... , In a turbulent world, people may find themselves in ... be their first move, but some situations can be avoided ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
Other Contents